BioCentury | Jun 26, 2020
Product Development

Pfizer, BioNTech on track to make hundreds of millions of COVID-19 vaccine doses this year

Pfizer and its partner BioNTech could obtain emergency use authorization for a COVID-19 vaccine as early as October, and expect to be able to produce hundreds of millions of doses in 2020 and a billion...
BioCentury | Jun 5, 2020
Product Development

Emergent playing key role in manufacturing COVID-19 vaccines via PPP set up for flu

If and when Americans are vaccinated against COVID-19, they might take a moment to thank another virus, H1N1 influenza. The country’s poor response to an H1N1 outbreak in 2009, including vaccine delays and shortages caused...
BioCentury | Jun 2, 2020
Product Development

CDMO Emergent, partner to three COVID-19 vaccine developers, gets $628M BARDA task order

HHS has agreed to award Emergent BioSolutions with up to $628 million to provide manufacturing services to COVID-19 vaccine developers with whom it has partnered, expanding an existing contract between Emergent and the department's Biomedical...
BioCentury | May 22, 2020
Product Development

Monkey rechallenge data provide COVID-19 neutralizing antibody benchmark for vaccine developers

As IMV and Vaxart prepare to advance their COVID-19 vaccine candidates into the clinic, monkey data from a Harvard-led team provide not only evidence of protective immunity following COVID-19 resolution, but also an antibody benchmark...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in therapeutic, vaccine and diagnostic COVID-19 programs, including GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients....
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
BC Innovations | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Extra | Nov 13, 2018
Company News

Management tracks: Anchiano, ContraFect

Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc. (OTCQB:ARPO). Anchiano also named Robert Connelly a director. He was a venture partner at Flagship Pioneering and...
BC Week In Review | Jul 13, 2018
Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial...
Items per page:
1 - 10 of 42
BioCentury | Jun 26, 2020
Product Development

Pfizer, BioNTech on track to make hundreds of millions of COVID-19 vaccine doses this year

Pfizer and its partner BioNTech could obtain emergency use authorization for a COVID-19 vaccine as early as October, and expect to be able to produce hundreds of millions of doses in 2020 and a billion...
BioCentury | Jun 5, 2020
Product Development

Emergent playing key role in manufacturing COVID-19 vaccines via PPP set up for flu

If and when Americans are vaccinated against COVID-19, they might take a moment to thank another virus, H1N1 influenza. The country’s poor response to an H1N1 outbreak in 2009, including vaccine delays and shortages caused...
BioCentury | Jun 2, 2020
Product Development

CDMO Emergent, partner to three COVID-19 vaccine developers, gets $628M BARDA task order

HHS has agreed to award Emergent BioSolutions with up to $628 million to provide manufacturing services to COVID-19 vaccine developers with whom it has partnered, expanding an existing contract between Emergent and the department's Biomedical...
BioCentury | May 22, 2020
Product Development

Monkey rechallenge data provide COVID-19 neutralizing antibody benchmark for vaccine developers

As IMV and Vaxart prepare to advance their COVID-19 vaccine candidates into the clinic, monkey data from a Harvard-led team provide not only evidence of protective immunity following COVID-19 resolution, but also an antibody benchmark...
BioCentury | Mar 31, 2020
Product Development

COVID-19 roundup: Qiagen, BD-BioMedomics, Rendu, Vaxart, Cobra, GigaGen, Houston Methodist, Anaqua-WideTrial

FDA’s emergency use authorization for a Qiagen test Tuesday comes amid a flurry of advancements in therapeutic, vaccine and diagnostic COVID-19 programs, including GigaGen’s unveiling of a polyclonal antibody program derived from convalescent COVID-19 patients....
BioCentury | Feb 15, 2020
Product Development

WHO mapping out COVID-19 vaccines

Scientists from biopharma companies, universities and regulatory agencies met at the WHO Feb. 11-12 to draw a roadmap for the development of vaccines to protect against COVID-19 amid a rapidly shifting terrain. While knowledge about...
BC Innovations | Jul 25, 2019
Product Development

The universe of universal flu vaccines

With at least 10 flu vaccines in the clinic that could confer protection against a wide range of strains, dispensing with the yearly seasonal vaccine may be in reach. Currently, seasonal flu vaccines consist of...
BioCentury | Jul 13, 2019
Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
BC Extra | Nov 13, 2018
Company News

Management tracks: Anchiano, ContraFect

Cancer company Anchiano Therapeutics Inc. (Tel Aviv:ANCN) appointed Stephen Hoffman chairman. He is CEO of Aerpio Pharmaceuticals Inc. (OTCQB:ARPO). Anchiano also named Robert Connelly a director. He was a venture partner at Flagship Pioneering and...
BC Week In Review | Jul 13, 2018
Clinical News

Vaxart's teslexivir misses in Phase II for anogenital warts

Vaxart Inc. (NASDAQ:VXRT) said twice-daily topical teslexivir (BTA074) 5% gel missed the primary endpoint of improving the complete clearance rate of baseline anogenital warts (condyloma) by week 16 vs. placebo in a Phase II trial...
Items per page:
1 - 10 of 42